LiTT + Cemiplimab for Brain Cancer

This trial examines the effectiveness of combining two treatments, Laser Interstitial Thermal Therapy (LiTT) and cemiplimab (an immunotherapy drug), for individuals with recurrent glioblastoma, a type of brain cancer. Participants will receive either LiTT with cemiplimab or LiTT with standard chemotherapy selected by their doctor. This trial may suit those whose glioblastoma has returned after completing initial treatments such as surgery or chemotherapy. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have received certain treatments like chemotherapy or radiation therapy within 2 weeks before starting the study treatment. It's best to discuss your specific medications with the trial team.

Previous studies have shown that Laser Interstitial Thermal Therapy (LiTT) is a safe option for treating brain tumors like glioblastomas. Research indicates that LiTT is minimally invasive, involving less cutting and being gentler on the body, which usually allows for a quick recovery. Patients often stay in the hospital for just 1-2 days after the procedure.

Cemiplimab, an immunotherapy drug already approved for certain types of cancer, has a well-understood safety profile. One study suggested that when used with LiTT, this combination is effective and generally well-tolerated by patients.

Researchers are excited about the combination of Laser Interstitial Thermal Therapy (LiTT) and cemiplimab for brain cancer because it offers a novel approach by pairing a precise, heat-based method with a cutting-edge immunotherapy. Unlike standard treatments that often rely solely on chemotherapy or radiation, LiTT directly targets and destroys tumor tissue using laser-induced heat, minimizing damage to surrounding areas. Cemiplimab, an immune checkpoint inhibitor, works differently by unleashing the body's immune system to attack cancer cells. This dual approach could potentially enhance treatment effectiveness and improve outcomes for patients with brain cancer.

Studies have shown that Laser Interstitial Thermal Therapy (LiTT) effectively treats brain tumors, including glioblastomas. This therapy uses a laser to heat and destroy tumor cells, extending life expectancy by about 2 months for some patients. Research indicates that LiTT can double survival rates for certain aggressive brain cancers, increasing the average survival time from 5.2 to 11.8 months. In this trial, participants in the experimental arm will receive LiTT combined with cemiplimab, an immune therapy, which may further enhance the body's ability to fight cancer cells. Meanwhile, participants in the control arm will receive LiTT followed by adjuvant chemotherapy. While LiTT is already a promising treatment, combining it with cemiplimab may lead to even better outcomes for patients with recurring glioblastoma.¹²³⁴⁵